These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 30451578)
1. Radiolabeled ultra-small Fe Sun H; Zhang B; Jiang X; Liu H; Deng S; Li Z; Shi H Nanomedicine (Lond); 2019 Jan; 14(1):5-17. PubMed ID: 30451578 [TBL] [Abstract][Full Text] [Related]
2. 99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast (T1/T2) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis. Xue S; Zhang C; Yang Y; Zhang L; Cheng D; Zhang J; Shi H; Zhang Y J Biomed Nanotechnol; 2015 Jun; 11(6):1027-37. PubMed ID: 26353592 [TBL] [Abstract][Full Text] [Related]
3. cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Yang X; Hong H; Grailer JJ; Rowland IJ; Javadi A; Hurley SA; Xiao Y; Yang Y; Zhang Y; Nickles RJ; Cai W; Steeber DA; Gong S Biomaterials; 2011 Jun; 32(17):4151-60. PubMed ID: 21367450 [TBL] [Abstract][Full Text] [Related]
4. Fe Wang C; Yan C; An L; Zhao H; Song S; Yang S J Mater Chem B; 2021 Sep; 9(37):7734-7740. PubMed ID: 34586149 [TBL] [Abstract][Full Text] [Related]
5. RGD-functionalized ultrasmall iron oxide nanoparticles for targeted T₁-weighted MR imaging of gliomas. Luo Y; Yang J; Yan Y; Li J; Shen M; Zhang G; Mignani S; Shi X Nanoscale; 2015 Sep; 7(34):14538-46. PubMed ID: 26260703 [TBL] [Abstract][Full Text] [Related]
6. Conjugation of iron oxide nanoparticles with RGD-modified dendrimers for targeted tumor MR imaging. Yang J; Luo Y; Xu Y; Li J; Zhang Z; Wang H; Shen M; Shi X; Zhang G ACS Appl Mater Interfaces; 2015 Mar; 7(9):5420-8. PubMed ID: 25695661 [TBL] [Abstract][Full Text] [Related]
7. Magnetic targeting combined with active targeting of dual-ligand iron oxide nanoprobes to promote the penetration depth in tumors for effective magnetic resonance imaging and hyperthermia. Chen L; Wu Y; Wu H; Li J; Xie J; Zang F; Ma M; Gu N; Zhang Y Acta Biomater; 2019 Sep; 96():491-504. PubMed ID: 31302299 [TBL] [Abstract][Full Text] [Related]
8. MR/NIRF Dual-Mode Imaging of αvβ3 Integrin-Overexpressing Tumors Using a Lipopeptide-Based Contrast Agent. Wang Q; Huang L; Zhu X; Zhou Y; Wang J; Su D; Liu L Mol Pharm; 2021 Dec; 18(12):4543-4552. PubMed ID: 34677979 [TBL] [Abstract][Full Text] [Related]
9. In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody. Ding N; Sano K; Kanazaki K; Ohashi M; Deguchi J; Kanada Y; Ono M; Saji H Mol Imaging Biol; 2016 Dec; 18(6):870-876. PubMed ID: 27351762 [TBL] [Abstract][Full Text] [Related]
10. [Construction of RGD10-NGR9 dual-targeting superparamagnetic iron oxide and its magnetic resonance imaging features in nude mice]. Wu QY; Shi JY; Zhang J; Zhang LQ; Zhao YM; Tang L; Chen Y; He XD; Liu H; Su B Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):808-13. PubMed ID: 24447476 [TBL] [Abstract][Full Text] [Related]
11. Surface ligand-regulated renal clearance of MRI/SPECT dual-modality nanoprobes for tumor imaging. Chen C; Huang B; Zhang R; Sun C; Chen L; Ge J; Zhou D; Li Y; Wu S; Qian Z; Zeng J; Gao M J Nanobiotechnology; 2024 May; 22(1):245. PubMed ID: 38735921 [TBL] [Abstract][Full Text] [Related]
12. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Liu S Mol Pharm; 2006; 3(5):472-87. PubMed ID: 17009846 [TBL] [Abstract][Full Text] [Related]
13. Bioengineered Magnetoferritin Nanoprobes for Single-Dose Nuclear-Magnetic Resonance Tumor Imaging. Zhao Y; Liang M; Li X; Fan K; Xiao J; Li Y; Shi H; Wang F; Choi HS; Cheng D; Yan X ACS Nano; 2016 Apr; 10(4):4184-91. PubMed ID: 26959856 [TBL] [Abstract][Full Text] [Related]
14. Peptide-Decorated Ultrasmall Superparamagnetic Nanoparticles as Active Targeting MRI Contrast Agents for Ovarian Tumors. Yin J; Yao D; Yin G; Huang Z; Pu X ACS Appl Mater Interfaces; 2019 Nov; 11(44):41038-41050. PubMed ID: 31618000 [TBL] [Abstract][Full Text] [Related]
15. One-step synthesis of water-dispersible ultra-small Fe3O4 nanoparticles as contrast agents for T1 and T2 magnetic resonance imaging. Wang G; Zhang X; Skallberg A; Liu Y; Hu Z; Mei X; Uvdal K Nanoscale; 2014 Mar; 6(5):2953-63. PubMed ID: 24480995 [TBL] [Abstract][Full Text] [Related]
16. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice. Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000 [TBL] [Abstract][Full Text] [Related]
17. Multicomponent, peptide-targeted glycol chitosan nanoparticles containing ferrimagnetic iron oxide nanocubes for bladder cancer multimodal imaging. Key J; Dhawan D; Cooper CL; Knapp DW; Kim K; Kwon IC; Choi K; Park K; Decuzzi P; Leary JF Int J Nanomedicine; 2016; 11():4141-55. PubMed ID: 27621615 [TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging contrast agent: cRGD-ferric oxide nanometer particle and its role in the diagnosis of tumor. Yi X; Ding Y; Zeng Y; Zhou C; Luo B; Meng S; Rui W; Zhao Y; Li W J Nanosci Nanotechnol; 2011 May; 11(5):3800-7. PubMed ID: 21780371 [TBL] [Abstract][Full Text] [Related]
19. Tunable and noncytotoxic PET/SPECT-MRI multimodality imaging probes using colloidally stable ligand-free superparamagnetic iron oxide nanoparticles. Pham TN; Lengkeek NA; Greguric I; Kim BJ; Pellegrini PA; Bickley SA; Tanudji MR; Jones SK; Hawkett BS; Pham BT Int J Nanomedicine; 2017; 12():899-909. PubMed ID: 28184160 [TBL] [Abstract][Full Text] [Related]